NEWSROOM

ImmuneTherapeutics

Immune Therapeutics Announces that Equity Partner, Cytocom, Inc., has Filed an Investigational New Drug Application to Conduct a Phase II Clinical Trial Evaluating CYTO-201 Treatment in COVID-19 Patients

Aug 7, 2020

Winter Park, FL., June 9, 2020, - Immune Therapeutics, Inc. (OTC PINK: IMUN), announced today that equity partner, Cytocom, Inc., has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to study CYTO-201 for the treatment of COVID-19. The submission has been reviewed by the COVID-19 Scientific/Technical Triage Team and has been assigned for review by the Division of Pulmonology, Allergy and Critical Care (DPACC), part of the Office of...

read more

Immune Therapeutics, Inc. Focusing to Drive Shareholder Value

Aug 7, 2020

Winter Park, FL, May 6, 2020 —Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”) is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced it has initiated a corporate plan to drive shareholder value. Recent economic events require that Immune revisit its business model and explore new opportunities to drive shareholder value. The Board of Directors is evaluating its...

read more

Immune Therapeutics, Inc. and Forte Biotechnology Intl Corp Sign Sub-Licensing Agreement for Animal Health Applications

Aug 7, 2020

Immune Therapeutics Announces Settlement with Major Creditors as part of licensing agreement Immune Therapeutics Announces Filing of 10K Extension Under SEC Allowance for COVID19 Disruption Forte Aims to Develop and Commercialize Lodonal and IRT=101 for the Treatment of Cancer and Inflammatory Disease in Companion Animals Orlando Florida April 16, 2020 – Immune Therapeutics Inc. (OTC PINK: IMUN), a clinical-stage pharmaceutical company, and Forte Biotechnology Intl Corp, a privately-held...

read more

Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19. Immune Therapeutics, Inc. Signs Binding Letter of Intent to Collaborate with Cytocom, Inc. to Develop Lodonal™ and Other Drugs for COVID-19; Other Drug Development Programs Also Moving Forward

Aug 7, 2020

ORLANDO, Florida, March 20, 2020 – Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”), Immune Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of highly innovative therapies for use in oncology, immunology and anti-inflammatory disease today announced the signing of a binding letter of intent to collaborate with Cytocom, Inc. (“Cytocom” or “CYTO”) for the development of Lodonal™ and IRT-101 for use...

read more

Immune Therapeutics, Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change

Aug 7, 2020

Immune Therapeutics, Inc. Files Amendment on 1000 to 1 Reverse and Name Change with the State of Florida Division of Corporations Awaiting Completion of FINRA Approval Process ORLANDO, Florida, March 9, 2020 – Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases and cancer today announced an update on the pending...

read more

Immune Therapeutics, Inc. Appoints New Independent Director

Aug 7, 2020

Fort Collins, Co., February 18, 2020 —Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”) is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced the appointment of Mr. Michael L. Sander to its Board of Directors who will succeed Jack Brewer who served on the Company’s Board of Directors since 2018 and Edward Teraskiewicz, who served on the Company’s Board of...

read more

Immune Therapeutics Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change

Aug 7, 2020

Awaiting completion of FINRA approval process ORLANDO, Fla., February 11, 2020 -- Immune Therapeutics, Inc. (OTC PINK: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases today announced an update on the pending 1000 to 1 reverse stock split and name change of Immune Therapeutics. Immune Therapeutics originally submitted the reverse and name request for...

read more

Categories

Mcap MediaWire - Costumer Service

Translate »